Isletopathy in type 2 diabetes mellitus: Implications of islet RAS, islet fibrosis, islet amyloid, remodeling, and oxidative stress

被引:63
|
作者
Hayden, Melvin R. [1 ]
Sowers, James R.
机构
[1] Univ Missouri, Sch Med, Dept Internal Med, Columbia, MO 65211 USA
[2] Univ Missouri, Sch Med, Dept Diabet Endocrinol & Metab, Columbia, MO 65211 USA
[3] Univ Missouri, Sch Med, Dept Pharmacol & Physiol, Columbia, MO 65211 USA
[4] Univ Missouri, Sch Med, Dept Diabet, Columbia, MO 65211 USA
[5] Univ Missouri, Sch Med, Cardiovasc Dis Res Grp, Columbia, MO 65211 USA
关键词
D O I
10.1089/ars.2007.1610
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This review focuses primarily on islet structural and functional changes related to an activated islet renin angiotensin system (RAS), islet oxidative-redox imbalance, the concurrence of islet fibrosis (pericapillary, intra- and peri-islet), and islet amyloid deposition ( pericapillary, intra- and peri-islet). The islet-acinar-portal vascular pathway and the emerging important anatomical and functional region, the islet-exocrine interface, are also discussed. Because there is an associated histopathological islet disease in type 2 diabetes mellitus (T2DM), the term isletopathy is discussed in detail. The isletopathy in T2DM is equally important as the other complications of diabetes. Special stains and special lighting ( bright field and crossed polarized light) are utilized, along with light and transmission electron microscopy, in order to better understand islet structural remodeling in T2DM. The importance of an isletopathy in T2DM is supported by numerous remodeling changes within the islet and the islet-exocrine interface. While some of the structural findings are only preliminary observations, additional investigation in this area should lead to the development of new pathophysiological concepts and new therapies regarding the prevention and treatment of T2DM.
引用
收藏
页码:891 / 910
页数:20
相关论文
共 50 条
  • [21] Inflammatory stress in islet β-cells: therapeutic implications for type 2 diabetes?
    Lytrivi, Maria
    Igoillo-Esteve, Mariana
    Cnop, Miriam
    CURRENT OPINION IN PHARMACOLOGY, 2018, 43 : 40 - 45
  • [22] Research progress on the correlation between islet amyloid peptides and type 2 diabetes mellitus
    Li, Guangzhi
    Zhang, Dongmei
    OPEN MEDICINE, 2025, 20 (01):
  • [23] Cytotoxic effects of human islet amyloid polypeptide on primary islet α-cells and β-cells:: Implications for understanding the pathogenesis of type 2 diabetes
    Cheng, Florence
    Marzban, Lucy
    DIABETES, 2007, 56 : A410 - A411
  • [24] Human islet amyloid polypeptide: A therapeutic target for the management of type 2 diabetes mellitus
    Roham, Pratiksha H.
    Save, Shreyada N.
    Sharma, Shilpy
    JOURNAL OF PHARMACEUTICAL ANALYSIS, 2022, 12 (04) : 556 - 569
  • [25] The role of Islet Amyloid PolyPeptide (IAPP)-membrane interactions in type 2 diabetes mellitus
    Engel, MFM
    de Kruijff, B
    Höppener, JWM
    Killian, JA
    FEBS JOURNAL, 2005, 272 : 236 - 236
  • [26] Higher Islet Amyloid Load in Men Than in Women With Type 2 Diabetes Mellitus
    Zhao, Hai-Lu
    Sui, Yi
    Guan, Jing
    He, Lan
    Lai, Fernand M. M.
    Zhong, Ding-Rong
    Yang, Di
    Baum, Larry
    Tong, Peter C. Y.
    Tomlinson, Brian
    Chan, Juliana C. N.
    PANCREAS, 2008, 37 (03) : E68 - E73
  • [27] THE RELATION OF ISLET AMYLOID TO THE CLINICAL TYPE OF DIABETES
    MALOY, AL
    LONGNECKER, DS
    GREENBERG, ER
    HUMAN PATHOLOGY, 1981, 12 (10) : 917 - 922
  • [28] Angiogenesis in islet hyperplasia and islet failure in type 2 diabetes
    Zhang, LJ
    Li, XQ
    Dias-Leme, C
    Treutelaar, M
    Burant, C
    DIABETES, 2004, 53 : A377 - A377
  • [29] Islet amyloid polypeptide gene promoter polymorphisms are not associated with Type 2 diabetes or with the Eseverity of islet amyloidosis
    Esapa, C
    Moffitt, JH
    Novials, A
    McNamara, CM
    Levy, JC
    Laakso, M
    Gomis, R
    Clark, A
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2005, 1740 (01): : 74 - 78
  • [30] Islet transplantation in type I diabetes mellitus
    Gerber, P. A.
    Lehmann, R.
    DIABETOLOGE, 2015, 11 (07): : 545 - 552